
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories anticipates its organic sales growth to remain robust, with projections for 2025 set between 6.0-7.0%, while achieving a 6.4% year-over-year increase with consensus sales of approximately $44.69 billion. Significant growth across its Electrophysiology, Structural Heart, and Diabetes segments, with organic increases of 13.7%, 11.3%, and 16.2% respectively, underlines the company’s expanding market presence and product adoption, particularly noted in emerging markets. Abbott's steadfast commitment to increasing dividends for over 50 consecutive years, coupled with a strong balance sheet, positions the company favorably for future growth and potential mergers and acquisitions.
Bears say
Abbott Laboratories is facing significant challenges due to ongoing Covid-19 testing revenue declines, with Q3'25 sales dropping to $69 million from $265 million in Q3'24, prompting a reevaluation of its sales outlook. Additionally, macroeconomic pressures such as inflation and foreign exchange fluctuations are contributing to lower-than-expected revenues and complicating the company's performance. Finally, the company has expressed concerns over specific product demand sensitivity, particularly with Cologuard, as well as the negative impact of funding cuts for HIV testing on its Rapid Diagnostics segment.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares